Quad Technologies Collaborates With University of Massachusetts Medical School To Highlight Benefits Of Novel Cell Separation Solution

Studies demonstrate highly viable, pure and completely magnetic bead-free isolated T-Cell populations from human umbilical cord blood samples using MagCloudz™ Cell Separation Kit

WOBURN, Mass.--(BUSINESS WIRE)--The rapid growth of cell-based immunotherapy research has led to an increase in demand for methods to isolate specific immune cell populations from heterogeneous samples with high viability, purity and recovery. Quad Technologies (“Quad”), is meeting this need with its MagCloudz™ Streptavidin Cell Separation Kits and has partnered with the University of Massachusetts Medical School to evaluate the performance of its novel cell separation solution for the enrichment and purification of CD3+ T-cells from human umbilical cord blood.

“Our collaboration with The University of Massachusetts was a great success and the results clearly demonstrated how our kits truly overcome the limitations of current approaches for cell separation.”

Results of the study with the University of Massachusetts Medical School demonstrated successful CD3+/CD45+ T-Cell enrichment from both peripheral and umbilical cord blood samples, with purity of the recovered T-Cell populations exceeding >95%. This high degree of purity, accompanied by high cell viability and the total absence of residual magnetic particles renders the MagCloudz-isolated T-Cells ideal for use in downstream translational applications.

Dr. Michael Brehm, Associate Professor of Program in Molecular Medicine at the University of Massachusetts Medical School led the study and discussed the details during a recent webinar entitled ‘Blood Derived T-Cell Enrichment Using a Purification Technology’ which can be viewed on demand at www.nature.com.

Sean Kevlahan, CEO of Quad Technologies commented “Our collaboration with The University of Massachusetts was a great success and the results clearly demonstrated how our kits truly overcome the limitations of current approaches for cell separation.”

Quad has also expanded its offering for the cell isolation workflow to include a magnetic stand supporting the magnetic cell separation steps of the MagCloudz kit workflow. The Q-Mag Magnetic Stand’s ergonomic design is ideal for manual use and enables easy transport of samples during incubation and vortexing steps. The stand accommodates up to sixteen 1.5ml-2.0ml microcentrifuge tubes and is available for purchase at http://quadtechnologies.com/shop/.

Quad will be demonstrating their technology capabilities in Booth #220 at the Cell & Gene Therapy World Conference taking place from January 25-27, 2016 in Washington, DC where Dr. Kevlahan will present the capabilities of MagCloudz during the “Technologies of Tomorrow” showcase theater.

In 2016, Quad Technologies plans to expand its collaborative reach with new partnerships focused on technology development and refinement for applications critical to regenerative medicine and immunotherapeutic areas.

About Quad Technologies

Established in 2013, Quad Technologies is a developer of a game changing novel cell separation technology for binding and releasing rare cells from surfaces. With a product driven business model, the company is committed to answering the needs of researchers working in cell separation applications – www.quadtechnologies.com